Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases

Biochemical and Biophysical Research Communications

Volumn 354, Issue 3, 2007, Pages 634-640

  Wang, Shu Qing ^a   Du, Qi Shi ^b,c   Chou, Kou Chen ^c  

^a TIANJIN UNIVERSITY   (China)

^b QINGDAO AGRICULTURAL UNIVERSITY   (China)

^c GORDON LIFE SCIENCE INSTITUTE   (United States)

Author keywords

Chicken influenza virus H5N1; Drug resistance; Homology modeling; Neuraminidase inhibitor

Indexed keywords

ALANINE; N ACETYL 2,3 DIDEHYDRO 2 DEOXYNEURAMINIC ACID; OSELTAMIVIR; SIALIDASE INHIBITOR; THREONINE; UNCLASSIFIED DRUG; VIRUS SIALIDASE; ZANAMIVIR;

ARTICLE; CHEMICAL STRUCTURE; DATA BASE; GENE MUTATION; HYDROPHILICITY; INFLUENZA; INFLUENZA VIRUS A; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION; THREE DIMENSIONAL IMAGING; VIRUS STRAIN;

ANIMALS; ANTIVIRAL AGENTS; BINDING SITES; CHICKENS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HYDROPHOBICITY; INFLUENZA A VIRUS, H5N1 SUBTYPE; MODELS, CHEMICAL; MOLECULAR SEQUENCE DATA; MUTATION; NEURAMINIDASE; OSELTAMIVIR; SEQUENCE ANALYSIS, PROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP; ZANAMIVIR;

INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE;

EID: 33846617350     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.12.235     Document Type: Article

References (45)

1. Claas E.C., de Jong J.C., van Beek R., Rimmelzwaan G.F., and Osterhaus A.D. Human influenza virus A/HongKong/156/97 (H5N1) infection. Vaccine 16 (1998) 977-978
2. Subbarao K., Klimov A., Katz J., Regnery H., Lim W., Hall H., Perdue M., Swayne D., Bender C., Huang J., Hemphill M., Rowe T., Shaw M., Xu X., Fukuda K., and Cox N. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279 (1998) 393-396
3. Smith B.J., McKimm-Breshkin J.L., McDonald M., Fernley R.T., Varghese J.N., and Colman P.M. Structural studies of the resistance of influenza virus neuramindase to inhibitors. J. Med. Chem. 45 (2002) 2207-2212
4. Horimoto T., and Kawaoka Y. Pandemic threat posed by avian influenza A viruses. Clin. Microbiol. Rev. 14 (2001) 129-149
5. McKimm-Breschkin J.L. Resistance of influenza viruses to neuraminidase inhibitors--a review. Antiviral Res. 47 (2000) 1-17
6. Lew W., Chen X., and Kim C.U. Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. Curr. Med. Chem. 7 (2000) 663-672
7. Dunn C.J., and Goa K.L. Zanamivir: a review of its use in influenza. Drugs 58 (1999) 761-784
8. Takeda-Shitaka M., Terashi G., Takaya D., Kanou K., Iwadate M., and Umeyama H. Protein structure prediction in CASP6 using CHIMERA and FAMS. Proteins 61 Suppl. 7 (2005) 122-127
9. Le Q.M., Kiso M., Someya K., Sakai Y.T., Nguyen T.H., Nguyen K.H., Pham N.D., Ngyen H.H., Yamada S., Muramoto Y., Horimoto T., Takada A., Goto H., Suzuki T., Suzuki Y., and Kawaoka Y. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437 (2005) 1108
10. Hurt A.C., Barr I.G., Hartel G., and Hampson A.W. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antiviral Res. 62 (2004) 37-45
11. Smith B.J., Colman P.M., Von Itzstein M., Danylec B., and Varghese J.N. Analysis of inhibitor binding in influenza virus neuraminidase. Protein Sci. 10 (2001) 689-696
12. Chou K.C. Review: structural bioinformatics and its impact to biomedical science. Curr. Med. Chem. 11 (2004) 2105-2134
13. Wei D.Q., Du Q.S., Sun H., and Chou K.C. Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands. Biochem. Biophys. Res. Commun. 344 (2006) 1048-1055
14. Needleman S.B., and Wunsch C.D. A general method applicable to the search for similarities in the amino acid sequence of two proteins. J. Mol. Biol. 48 (1970) 443-453
15. Gotoh O. Optimal alignment between groups of sequences and its application to multiple sequence alignment. Comput. Appl. Biosci. 9 (1993) 361-370
16. Chou K.C. Modelling extracellular domains of GABA-A receptors: subtypes 1, 2, 3, and 5. Biochem. Biophys. Res. Commun. 316 (2004) 636-642
17. Chou K.C. Modeling the tertiary structure of human cathepsin-E. Biochem. Biophys. Res. Commun. 331 (2005) 56-60
18. Devereux J. Genetic Computer Group (GCG) (1994), Madison, Wisconsin
19. Kim C.U., Lew W., Williams M.A., Wu H., Zhang L., Chen X., Escarpe P.A., Mendel D.B., Laver W.G., and Stevens R.C. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. J. Med. Chem. 41 (1998) 2451-2460
20. Finley J.B., Atigadda V.R., Duarte F., Zhao J.J., Brouillette W.J., Air G.M., and Luo M. Novel aromatic inhibitors of influenza virus neuraminidase make selective interactions with conserved residues and water molecules in the active site. J. Mol. Biol. 293 (1999) 1107-1119
21. Colman P.M., Hoyne P.A., and Lawrence M.C. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J. Virol. 67 (1993) 2972-2980
22. Zhou N.N., Shortridge K.F., Claas E.C., Krauss S.L., and Webster R.G. Rapid evolution of H5N1 influenza viruses in chickens in Hong Kong. J. Virol. 73 (1999) 3366-3374
23. Chou K.C., Wei D.Q., and Zhong W.Z. Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochem. Biophys. Res. Commun. 308 (2003) 148-151 (Erratum: K.C. Chou, D.Q. Wei, W.Z. Zhong, Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS, Biochem. Biophys. Res. Commun. 310 (2003) 675)
24. Chou K.C., Wei D.Q., Du Q.S., Sirois S., and Zhong W.Z. Review: progress in computational approach to drug development against SARS. Curr. Med. Chem. 13 (2006) 3263-3270
25. Wei D.Q., Zhang R., Du Q.S., Gao W.N., Li Y., Gao H., Wang S.Q., Zhang X., Li A.X., Sirois S., and Chou K.C. Anti-SARS drug screening by molecular docking. Amino Acids 31 (2006) 73-80
26. Wei D.Q., Sirois S., Du Q.S., Arias H.R., and Chou K.C. Theoretical studies of Alzheimer's disease drug candidate [(2,4-dimethoxy) benzylidene]-anabaseine dihydrochloride (GTS-21) and its derivatives. Biochem. Biophys. Res. Commun. 338 (2005) 1059-1064
27. Zhou G.P., and Troy II F.A. NMR study of the preferred membrane orientation of polyisoprenols (dolichol) and the impact of their complex with polyisoprenyl recognition sequence peptides on membrane structure. Glycobiology 15 (2005) 347-359
28. Zhou G.P., and Troy F.A. NMR studies on how the binding complex of polyisoprenol recognition sequence peptides and polyisoprenols can modulate membrane structure. Curr. Protein Peptide Sci. 6 (2005) 399-411
29. Wang S.Q., Du Q.S., Zhao K., Li A.X., Wei D.Q., and Chou K.C. Virtual screening for finding natural inhibitor against cathepsin-L for SARS therapy. Amino Acids (2006) DOI 10.1007/s00726-00006-00403-00721
30. Wei H., Zhang R., Wang C., Zheng H., Chou K.C., and Wei D.Q. Molecular insights of SAH enzyme catalysis and their implication for inhibitor design. J. Theor. Biol. (2006) doi.org/10.1016/j.jtbi.2006.1009.1011
31. Du Q.S., Wang S., Wei D.Q., Sirois S., and Chou K.C. Molecular modelling and chemical modification for finding peptide inhibitor against SARS CoV Mpro. Anal. Biochem. 337 (2005) 262-270
32. Zhang R., Wei D.Q., Du Q.S., and Chou K.C. Molecular modeling studies of peptide drug candidates against SARS. Med. Chem. 2 (2006) 309-314
33. Ewing T.J., Makino S., Skillman A.G., and Kuntz I.D. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J. Comput. Aided Mol. Des. 15 (2001) 411-428
34. Colman P.M., Tulip W.R., Varghese J.N., Tulloch P.A., Baker A.T., Laver W.G., Air G.M., and Webster R.G. Three-dimensional structures of influenza virus neuraminidase-antibody complexes. Philos. Trans. R. Soc. Lond. B Biol. Sci. 323 (1989) 511-518
35. Chou K.C., Watenpaugh K.D., and Heinrikson R.L. A Model of the complex between cyclin-dependent kinase 5(Cdk5) and the activation domain of neuronal Cdk5 activator. Biochem. Biophys. Res. Commun. 259 (1999) 420-428
36. Kiso M., Mitamura K., Sakai-Tagawa Y., Shiraishi K., Kawakami C., Kimura K., Hayden F.G., Sugaya N., and Kawaoka Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364 (2004) 759-765
37. Du Q.S., Mezey P.G., and Chou K.C. Heuristic Molecular Lipophilicity Potential (HMLP): A 2D-QSAR Study to LADH of Molecular Family Pyrazole and Derivatives. J. Comput. Chem. 26 (2005) 461-470
38. Gubareva L.V., Webster R.G., and Hayden F.G. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res. 53 (2002) 47-61
39. B. S. Kamps, C. Hoffmann, W. Preiser, Influenza report, www.InfluenzaReport.com, 2006.
40. Du Q.S., Liu P.J., and Mezey P.G. Theoretical derivation of heuristic molecular lipophilicity potential: a quantum chemical description for molecular solvation. J. Chem. Inf. Model 45 (2005) 347-353
41. Du Q.S., Li D.P., He W.Z., and Chou K.C. Heuristic molecular lipophilicity potential (HMLP): lipophilicity and hydrophilicity of amino acid side chains. J. Comput. Chem. 27 (2006) 685-692
42. Ison M.G., Gnann Jr. J.W., Nagy-Agren S., Treannor J., Paya C., Steigbigel R., Elliott M., Weiss H.L., and Hayden F.G. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir. Ther. 8 (2003) 183-190
43. Hayden F.G., Osterhaus A.D., Treanor J.J., Fleming D.M., Aoki F.Y., Nicholson K.G., Bohnen A.M., Hirst H.M., Keene O., and Wightman K. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N. Engl. J. Med. 337 (1997) 874-880
44. Calfee D.P., Peng A.W., Cass L.M., Lobo M., and Hayden F.G. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob. Agents Chemother. 43 (1999) 1616-1620
45. de Jong M.D., Tran T.T., Truong H.K., Vo M.H., Smith G.J., Nguyen V.C., Bach V.C., Phan T.Q., Do Q.H., Guan Y., Peiris J.S., Tran T.H., and Farrar J. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353 (2005) 2667-2672